CCS
ARNA

Crosspoint Capital Strategies’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Crosspoint Capital Strategies’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-456
Closed -$155K – 107
2017
Q4 		$155K Buy
456
+120
+36% +$3.42K 0.01% 62
2017
Q3 		$9K Buy
+336
New +$7.71K 0.01% 87

Other funds holding ARNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Crosspoint Capital Strategies's ARNA Position: Q1 2018 in Review

Crosspoint Capital Strategies sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2018, closing a stake of 456 shares — an estimated $155K sold.

Crosspoint Capital Strategies first reported a position in ARNA in Q3 2017 and held it in 2 quarters. The position peaked at $155K in Q4 2017. 170 funds tracked by Wall St. Rank hold ARNA as of Q1 2018.

  • Crosspoint Capital Strategies reported no remaining Arena Pharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 456 Arena Pharmaceuticals Inc shares in Q1 2018, an estimated $155K.
  • Crosspoint Capital Strategies first reported a position in Arena Pharmaceuticals Inc in Q3 2017 and held it in 2 quarters.
  • Crosspoint Capital Strategies's Arena Pharmaceuticals Inc position peaked at $155K in Q4 2017.
  • 170 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2018.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2018, filed 14 May 2018.